Corrigendum to ‘Phosphorylated Rasal2 facilitates breast cancer progression’

In this Research Paper, the affiliations of the following authors should have been as follows: Xuan Wang (a,c), Meng-Yue Liu (a), Zhong-Ming Qian (a,c) As a result, the order in which two of the institutions were listed changes to: (a) Institute of Translational & Precision Medicine, Nantong University, 19 Qi Xiu Road, Nantong, JS 226019, China (c) Department of Pharmacology and Biochemistry, Fudan University School of Pharmacy, 826 Zhangheng Road, Pu Dong, Shanghai 201203, China. The authors apologise for this oversight. Phosphorylated Rasal2 facilitates breast cancer progressionp-Rasal2 facilitates tumour progression in both ER+ and ER− breast cancers. The ratio of p-Rasal2/non-p-Rasal2 in ER+ and ER− breast cancers is one of the factors deciding the role of Rasal2 (or total Rasal2) as a suppressor in ER+ breast cancers or as a promoter in ER− breast cancers. Targeting the phosphorylation of Rasal2 machinery may therefore be useful as a therapy to restrain breast cancer progression by reducing p-Rasal2/non-p-Rasal2 ratio, especially in ER− breast cancers. Full-Text PDF Open Access

Abstract licence: CC BY-NC

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.